Research programme: B-Raf kinase inhibitors - Pfizer

Drug Profile

Research programme: B-Raf kinase inhibitors - Pfizer

Alternative Names: PF-04880594; WYE-130600

Latest Information Update: 14 Sep 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Sep 2011 Preclinical development is ongoing in US
  • 26 Mar 2009 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top